GlassScriptPhysician profile
Andrew O White
NPI 1295769768
$1,461.22
in general payments reported to CMS, 2019-2025
25 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $43.05 · 2021: $82.63 · 2022: $155 · 2023: $189 · 2024: $359 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $334.28 | 2019-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $235.61 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $120.29 | 2023-2025 | Jardiance, Mounjaro |
| Pfizer INC. | $95.40 | 2021-2025 | |
| Dexcom, INC. | $80.69 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $68.64 | 2024-2025 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $60.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $55.11 | 2022-2024 | |
| Astellas Pharma US INC | $38.39 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $35.97 | 2022-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $32.16 | 2024 | Rexulti |
| Amgen INC. | $30.98 | 2020-2025 | Repatha, Otezla |
| Genentech USA, INC. | $30.63 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.69 | 2025 | |
| Corcept Therapeutics | $26.35 | 2024 | Korlym |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $25.37 | 2025 | |
| Axsome Therapeutics, INC. | $23.65 | 2023 | Sunosi |
| Scilex Pharmaceuticals INC. | $22.18 | 2023 | Ztlido |
| Abbott Laboratories | $19.95 | 2023 | Freestyle Libre 2 |
| Sumitomo Pharma America, INC. | $18.57 | 2024 | Gemtesa |
| Noven Pharmaceuticals, INC. | $18.26 | 2024 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $16.38 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.31 | 2024 | Breztri |
| Antares Pharma, INC. | $15.08 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.